CG Oncology (CGON) Equity Ratio (2023 - 2025)
CG Oncology's Equity Ratio history spans 3 years, with the latest figure at 0.95 for Q4 2025.
- For Q4 2025, Equity Ratio fell 2.15% year-over-year to 0.95; the TTM value through Dec 2025 reached 0.95, down 2.15%, while the annual FY2025 figure was 0.95, 2.15% down from the prior year.
- Equity Ratio reached 0.95 in Q4 2025 per CGON's latest filing, up from 0.94 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.98 in Q1 2024 to a low of 0.62 in Q4 2023.
- Average Equity Ratio over 3 years is 0.79, with a median of 0.97 recorded in 2025.
- Peak YoY movement for Equity Ratio: skyrocketed 257.31% in 2024, then fell 3.04% in 2025.
- A 3-year view of Equity Ratio shows it stood at 0.62 in 2023, then surged by 257.31% to 0.97 in 2024, then decreased by 2.15% to 0.95 in 2025.
- Per Business Quant, the three most recent readings for CGON's Equity Ratio are 0.95 (Q4 2025), 0.94 (Q3 2025), and 0.96 (Q2 2025).